See ya, CO2

Houston company is solving the energy and space industries' carbon dioxide problems with synthetic photosynthesis

The Karimi siblings have created a way to synthetically convert CO2 into glucose, and they are targeting the energy and aerospace industries for their technology. Courtesy of Cemvita Factory

Houston-based Cemvita Factory is unlike most startups. Before even knowing what industry they were going to affect, Moji Karimi and his sister, Tara, established their company, which uses synthetic photosynthesis — the process of turning carbon dioxide into glucose for plants.

"In some ways, this company started with the solution, rather than the problem," Moji Karimi, co-founder of Cemvita, says. "Then we said, 'if we could replicate photosynthesis, what problems can we solve?'"

Once the technology was set in place, Karimi, who has a background in oil and gas drilling, says he identified the energy industry in need of something like this. He says he saw an increased pressure on large energy companies to adapt sustainable ways to get rid of the CO2 that is produced as a result of drilling.

More and more companies are investing in a process called carbon dioxide capturing — but it's expensive and not yet cost efficient for energy companies to commit to. But that's changing. Karimi says the process that once cost $600 per ton of CO2 now can be found as cheap as $30.

With his sister's technology, Karimi says they can take that captured carbon dioxide and turn it into other chemicals too. Each oil and gas company client can specify what they want to turn it into and, for less than $100,000, Cemvita will run a pilot program for them. Cemvita sells the exclusive rights to the technology, but still maintains its IP.

"We go to these companies and say, 'What do you want to convert CO2 into?,'" Karimi says. "Then, we do a quick pilot in six months in our lab, and we show them the metrics. They decide if they want to scale it up."

What seemed like another obvious industry for this process was aerospace. Many companies involved in aerospace exploration have Mars on the mind, and the planet's atmosphere is over 95 percent carbon dioxide. Plus, Cemvita can provide a more sustainable way to dispose of CO2 onboard spacecrafts. The current practice is essentially just discarding it by filtering it off the spaceship.

Putting a system in place
Cemvita was founded in August of 2017 and used 2018 to really establish itself. The company took second place at Dubai's Mohammed bin Rashid Space Centre Innovation Challenge and completed the accelerator program at Capital Factory.

Realizing the process is new and without the backing of an educational institution, Karimi says he and his sister needed a way to answer any questions and concerns, so Tara wrote a book. "Molecular Mechanisms of Autonomy in Biological Systems" is published by Springer.

Karimi also lead a talk at Tudor Pickering Holt's Energy Disruptor conference. His discussion, "From Mars to Midland," garnered a lot of interest from energy professionals.

The future is now
Karimi says 2019 is all about execution. He never thought he and his sister would overlap their industries, but now there's more of a need of interdisciplinary collaboration than ever before.

"There are a lot of opportunities bringing a proven science or technology from one industry into another to solve problems," he says.

The company has growth plans this year. The team has bootstrapped everything financially so far, but is looking for its first funding round in the middle of 2019. And, as far as the Karimi siblings are concerned, they are in the exact right place to grow.

"We're in Houston, and we have a technology that is from biotech and have applications in the space industry and the energy industry," Karimi says. "There would not have been any better place for us in the country than Houston."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted